[1] KATZ P O, GERSON L B, VELA M F. Guidelines for the diagnosis and management of gastroesophageal reflux disease[J]. Am J Gastroenterol,2013,108(3):308-328. doi:  10.1038/ajg.2012.444
[2] ZACHARIAH R A, GOO T, LEE R H. Mechanism and pathophysiology of gastroesophageal reflux disease[J]. Gastrointest Endosc Clin N Am,2020,30(2):209-226. doi:  10.1016/j.giec.2019.12.001
[3] Iwakiri K, Kinoshita Y, Habu Y, et al. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015[J]. J Gastroenterol,2016,51(8):751-767. doi:  10.1007/s00535-016-1227-8
[4] EL ROUBY N, LIMA J J, JOHNSON J A. Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine[J]. Expert Opin Drug Metab Toxicol,2018,14(4):447-460. doi:  10.1080/17425255.2018.1461835
[5] IWAKIRI K. Treatment strategy for standard-dose proton pump inhibitor-resistant reflux esophagitis[J]. J Nippon Med Sch,2017,84(5):209-214. doi:  10.1272/jnms.84.209
[6] 刘腾, 徐春敏, 赵志刚. 新型质子泵抑制剂艾普拉唑的综合评价与临床应用进展[J]. 药品评价, 2016, 13(22):8-12. doi:  10.3969/j.issn.1672-2809.2016.22.002
[7]

DE BORTOLI N, MARTINUCCI I, GIACCHINO M, et al. The pharmacokinetics of ilaprazole for gastro-esophageal reflux treatment[J]. Expert Opin Drug Metab Toxicol,2013,9(10):1361-1369. doi:  10.1517/17425255.2013.813018
[8] 李婷, 赵紫楠, 胡欣, 等. 艾普拉唑肠溶片治疗十二指肠溃疡的快速卫生技术评估[J]. 中国药学杂志, 2020, 55(13):1111-1116.
[9]

ZHANG J X, GE L, HILL M, et al. Standard-dose proton pump inhibitors in the initial non-eradication treatment of duodenal ulcer: systematic review, network meta-analysis, and cost-effectiveness analysis[J]. Front Pharmacol,2019,9:1512. doi:  10.3389/fphar.2018.01512
[10]

LUNDELL L R, DENT J, BENNETT J R, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification[J]. Gut,1999,45(2):172-180. doi:  10.1136/gut.45.2.172
[11] 范学锋. 艾普拉唑对反流性食管炎临床治疗价值分析[J]. 人人健康, 2019(22):225.
[12]

XUE Y, QIN X H, ZHOU L Y, et al. A randomized, double-blind, active-controlled, multi-center study of ilaprazole in the treatment of reflux esophagitis[J]. Clin Drug Investig,2016,36(12):985-992. doi:  10.1007/s40261-016-0446-3
[13] 胡爱萍, 李娜. 艾普拉唑治疗反流性食管炎的疗效与药物经济学分析[J]. 蛇志, 2016, 28(1):47-48. doi:  10.3969/j.issn.1001-5639.2016.01.023
[14] 霍结容. 艾普拉唑治疗反流性食管炎临床效果观察及药物经济学研究[J]. 广东微量元素科学, 2015, 22(6):56-59. doi:  10.16755/j.cnki.issn.1006-446x.2015.06.008
[15] 牛省利. 艾普拉唑治疗反流性食管炎的疗效观察[J]. 中国实用医药, 2013, 8(19):186-187. doi:  10.3969/j.issn.1673-7555.2013.19.134
[16] 艾冬华. 艾普拉唑治疗反流性食管炎临床效果观察及药物经济学分析[J]. 中国基层医药, 2013, 20(19):2902-2904. doi:  10.3760/cma.j.issn.1008-6706.2013.19.010
[17] 宋芳, 何辉, 沈磊, 等. 艾普拉唑治疗反流性食管炎180例的疗效及安全性[J]. 中国新药杂志, 2012, 21(8):905-907.
[18] 郭永谊, 祁真, 苟新敏, 等. 艾普拉唑治疗反流性食管炎的药物经济学评价[J]. 中国药物评价, 2012, 29(3):235-236. doi:  10.3969/j.issn.2095-3593.2012.03.015
[19] 李东复, 陈永胜, 马静婷, 等. 艾普拉唑治疗反流性食管炎的临床研究[J]. 中华消化杂志, 2011, 31(4):264-265. doi:  10.3760/cma.j.issn.0254-1432.2011.04.012
[20]

HERREGODS T V K, BREDENOORD A J, SMOUT A J P M. Pathophysiology of gastroesophageal reflux disease: new understanding in a new era[J]. Neurogastroenterol Motil,2015,27(9):1202-1213. doi:  10.1111/nmo.12611
[21]

KIL B J, KIM I W, SHIN C Y, et al. Comparison of IY81149 with omeprazole in rat reflux oesophagitis[J]. J Auton Pharmacol,2000,20(5-6):291-296. doi:  10.1046/j.1365-2680.2000.00192.x
[22]

PERICLOU A P, GOLDWATER R, LEE S M, et al. A comparative pharmacodynamic study of IY-81149 versus omeprazole in patients with gastroesophageal reflux disease[J]. Clin Pharmacol Ther,2000,68(3):304-311. doi:  10.1067/mcp.2000.109155
[23]

SONG I J, KIM H K, LEE N K, et al. Prospective single arm study on the effect of ilaprazole in patients with heartburn but no reflux esophagitis[J]. Yonsei Med J,2018,59(8):951-959. doi:  10.3349/ymj.2018.59.8.951
[24]

HIGUCHI K, JOH T, NAKADA K, et al. Is proton pump inhibitor therapy for reflux esophagitis sufficient?: a large real-world survey of Japanese patients[J]. Intern Med,2013,52(13):1447-1454. doi:  10.2169/internalmedicine.52.0349
[25]

WANG R X, WANG J, HU S Q. Study on the relationship of depression, anxiety, lifestyle and eating habits with the severity of reflux esophagitis[J]. BMC Gastroenterol,2021,21(1):127. doi:  10.1186/s12876-021-01717-5
[26]

HUNGIN A P S, MOLLOY-BLAND M, SCARPIGNATO C. Revisiting Montreal: new insights into symptoms and their causes, and implications for the future of GERD[J]. Am J Gastroenterol,2019,114(3):414-421. doi:  10.1038/s41395-018-0287-1
[27]

JAVADI S A H S, SHAFIKHANI A A. Anxiety and depression in patients with gastroesophageal reflux disorder[J]. Electron Physician,2017,9(8):5107-5112. doi:  10.19082/5107
[28]

YU Y, FANG D, FAN L, et al. Efficacy and safety of esomeprazole with flupentixol/melitracen in treating[J]. J Gastroenterol Hepatol,2014,29(6):1200-1206. doi:  10.1111/jgh.12552
[29]

YOSHIDA N, KAMADA K, TOMATSURI N, et al. Management of recurrence of symptoms of gastroesophageal reflux disease: synergistic effect of rebamipide with 15mg lansoprazole[J]. Dig Dis Sci,2010,55(12):3393-3398. doi:  10.1007/s10620-010-1166-9